ARWR241220P22000
- 0.70
- +0.38+118.75%
Arrowhead Pharmaceuticals Newsroom
B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $51
B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating
Arrowhead Pharmaceuticals: Positioned for Growth With Strategic Partnerships and SiRNA Advancements
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating
Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) Have Lost 66%, as Stock Drops 9.3% This Past Week
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Arrowhead Pharmaceuticals Price Target Raised to $80.00/Share From $60.00 by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
Arrowhead Pharmaceuticals Files Request to Initiate Phase 1/2a Trial of Obesity Treatment
Express News | Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of Aro-Alk7 for the Treatment of Obesity
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Trending Stocks This Week as Holiday Season Begins With Thanksgiving Break
Express News | Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR) and Sanofi (OtherSNYNF)
Arrowhead Pharmaceuticals Faces Distribution Risks With Vanscoy Reliance